revis model estim reflect risk-
adjust approach long-term pipelin
publish revis model rais long-term sale ep growth
re-built model re-draft project consist way
formul project name univers includ fx chang
organ growth due acquisit divestitur new project also reflect
revis long-term pharma project line view manag continu
invest deliv sustain growth also fine tune ep estim
beyond investor remain understand preoccupi jnj on-going litig
upcom feder mdl schedul begin next month continu expect
perform stock improv investor gain clariti regard rang
potenti liabil face compani reiter outperform rate target
minor chang near-term substanti chang beyond
signific chang relat pharma estim driven detail
risk-adjust approach late-stag pipelin expect manag
back-fil pressur gener biosimilar via partner licens strateg
invest estim jnj pipelin add ww pharma growth
risk-adjust basi nearli offset biosimilar pressur remicad
expect strong underli growth drive solid perform given
decreas magnitud declin zytiga remicad return growth xarelto
eas fx continu strong perform jnj key high-growth busi like
intervent solut darzalex imbruvica stelara tremfya expect top line
growth acceler vs report organ basi
valuat target price unchang base ebitda unchang
multipl estim ebitda bil bil previous risk
unexpect challeng pharma product pipelin delay greater pressur drug
price unexpect advers impact litig regulatory/qu issu
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek
busi compani cover research report result investor awar firm may conflict
interest could affect object report investor consid report singl factor make
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
johnson johnson hold compani engag
 manufactur sale rang product health care
field oper compani organ busi segment
one-year valuat scenario base
ev/ebitda ebitda bil
scenario base high-growth segment grow
growth grow
one-year valuat grey scenario base
ev/ebitda grey ebitda bil
grey scenario base high-growth segment grow
growth grow
 close
revenu earn build analysi
includ seri chart next page illustr key put take
reflect new project bridg growth sale ep
key element drive improv growth eas
impact gener biosimilar competit remicad zytiga dollar term
rel modest project impact fx compar partial offset
eas headwind project step asset sale divestitur
compar report incom past expect
compani manag year-over-year variabl mix improv oper
core perform pipelin contribut oper expens manag
figur ep build estim line item contribut
figur revenu build major busi line mm
figur pharma revenu build major driver
figur devic revenu build major busi line mm
note sale adjust partial year impact divestitur lifescan diabet
figur consum revenu build major busi line mm
chang model
made modest adjust estim sale ep howev
increas project jnj pharma busi
beyond increas long-term pharma estim driven
primarili detail risk-adjust model jnj near-term pipelin
assumpt manag make strateg invest forg addit partner
licens agreement back-fil impact gener competit
consist chang made modest adjust ep estim
thru signific increas beyond
figur chang model
compani mention price
matt miksic vik chopra certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
